Results 271 to 280 of about 127,740 (362)

Characteristics of changes in bone mineral density and body composition in obesity patients after metabolic and bariatric surgery: A prospective cohort study

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 9, Page 4968-4977, September 2025.
Abstract Aims To explore the changes in bone mineral density (BMD) and body composition in patients after bariatric surgery using dual‐energy X‐ray absorptiometry (DXA) and quantitative computed tomography (QCT), analyse the relationships between these changes and weight loss, and the correlations between the parameters of DXA and QCT.
Xiaoqing Yuan   +10 more
wiley   +1 more source

Cholecystokinin: Clinical aspects of the new biology

open access: yesJournal of Internal Medicine, Volume 298, Issue 3, Page 251-267, September 2025.
Abstract Cholecystokinin (CCK) is a classic gut hormone that has been known for almost a century to regulate gallbladder emptying, pancreatic enzyme secretion, and gastrointestinal motor activity. In 1968, the CCK structure was identified by Viktor Mutt and Erik Jorpes from porcine gut extracts as a peptide of 33 amino acid residues.
Jens F. Rehfeld
wiley   +1 more source

N6‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastasis

open access: yesCancer Communications, Volume 45, Issue 8, Page 941-965, August 2025.
Abstract Background Gastric cancer peritoneal metastasis is clinically challenging, given the limited treatment options and poor prognosis. The molecular mechanisms that precede gastric cancer peritoneal metastasis, known as the pre‐metastatic niche (PMN), and its relationship with N6‐methyladenosine (m6A) modification remain unclear.
Song Li   +23 more
wiley   +1 more source

Nutritional and Biochemical Outcomes After Total Versus Subtotal Gastrectomy: Insights into Early Postoperative Prognosis. [PDF]

open access: yesNutrients
Akad F   +11 more
europepmc   +1 more source

Efficacy and Safety of a 3‐Weekly TS‐1 Adjuvant Regimen in Advanced Gastric Cancer: A Pilot Study

open access: yesCancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Background TS‐1 at 80 mg/m2/day for 4 weeks followed by a 2‐week rest is standard adjuvant therapy for stage II/III Advanced Gastric Cancer (AGC). TS‐1 for 1 year (8 courses) is highly recommended. We investigated the efficacy and safety of an adjuvant 3‐weekly TS‐1 regimen for AGC.
Jihong Bae   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy